Company Profile

Zars Inc (AKA: Zars Pharma Inc)
Profile last edited on: 12/1/2023      CAGE: 5LGZ4      UEI: HDZWBGHT43H9

Business Identifier: Products for pain, anxiety disorders and nausea
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1142 West 2320 South
Salt Lake City, UT 84119
   (801) 350-0202
Location: Single
Congr. District: 04
County: Salt Lake

Public Profile

ZARS develops new and innovative products for pain therapy. Immediate efforts are focused on the delivery of existing, FDA cleared molecules and formulations. While ZARS has no intentions of pursuing new drug discovery, it has developed several novel formulations of existing drugs and will continue to do so. ZARS is a developer of proprietary products to administer drugs non-invasively through or into the skin using their patented heat delivery, or CHADD, technology. ZARS intends to become a leader in the field of transdermal drug delivery and in the development and marketing of specialty pharmaceutical products, with specific emphasis in the field of pain management

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2001 1 NIH $142,248
Project Title: Controlled Heat-Aided Transdermal Drug Delivery:Fentanyl

Key People / Management

  Robert Lippert -- President and CEO

  Michael A Ashburn -- Executive Vice President of Clinical and Regulatory Affairs, Founder

  Greg Ayers -- Chief Financial Officer

  Greg Fischer -- Vice President of Manufacturing Operations

  Larry Rigby

  Jie Zhang -- CSO, Founder

Company News

There are no news available.